326030.KS SK Biopharmaceuticals Co., Ltd.
KSCHealthcareAs of 2026-08-09 03:17
Why 326030.KS matters now
SK Biopharmaceuticals Co., Ltd. (326030.KS) is a Korea stock in Healthcare. The latest InvestLog snapshot shows ₩85,400.00 with +2.28% on the session and ₩6.69T in market capitalization.
Valuation context is available even where detailed statement rows are sparse: InvestLog currently shows P/E 17.27, gross margin 65.3%, and operating margin 35.2%.
Valuation
P/E (TTM)
17.27
PEG
—
P/B
7.18
P/S
7.76
EV/EBITDA
27.71
DCF Value
—
FCF Yield
2.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
65.3%
Operating Margin
35.2%
Net Margin
46.6%
ROE
53.2%
ROA
30.4%
ROIC
29.6%
Listing Info
Market
Korea
Exchange
KSC
Currency
KRW
Sector
Healthcare
Industry
Biotechnology
Country
KR
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.